Candel Therapeutics, Inc.
CADL
$9.79
$0.323.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.51% | 30.80% | 56.40% | 55.72% | -5.92% |
| Total Depreciation and Amortization | -23.88% | -14.65% | -6.74% | -1.71% | 0.31% |
| Total Amortization of Deferred Charges | 169.26% | 33.33% | -50.99% | -41.54% | -30.21% |
| Total Other Non-Cash Items | -55.54% | -113.29% | -153.23% | -147.31% | 180.83% |
| Change in Net Operating Assets | 120.20% | 533.82% | -154.92% | 75.64% | -29.51% |
| Cash from Operations | -75.48% | -41.77% | -17.21% | 3.15% | 14.63% |
| Capital Expenditure | -10,391.67% | -3,568.75% | -201.67% | 77.30% | 96.32% |
| Sale of Property, Plant, and Equipment | -- | -- | 35.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -10,166.67% | -3,400.00% | -285.00% | 74.13% | 96.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 7.67% | -27.99% | -49.99% | -139.98% | -499.88% |
| Issuance of Common Stock | 9.74% | -80.11% | 1,172.82% | 2,353.45% | 25,061.41% |
| Repurchase of Common Stock | -- | -- | -472.73% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 62.05% | -40.50% | 4,535.62% | 19,085.24% | 6,907.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.73% | -74.38% | 366.43% | 360.29% | 298.10% |